Scientific Literacy Essay Isabella Hollingsworth BIO293

Cardiac Arrest is a life-threatening medical emergency that occurs when the heart suddenly stops beating. It is responsible for the sudden cessation of blood flow to the heart, causing a loss of heart function. This condition can result from various risk factors including cardiovascular conditions such as coronary artery disease, arrhythmias, and previous heart attacks. Lifestyle factors like high blood pressure, diabetes, smoking, and obesity are also risk factors. Symptoms of cardiac arrest can include loss of consciousness, heart palpitations, dizziness, lightheadedness and weakness. Treatments include quickly restoring heart function through interventions like CPR and defibrillation. Early and effective use of Automated External Defibrillators (AEDs) can significantly improve survival chances by resetting the heart's rhythm.

The prevalence of cardiac arrest in the U.S. is notable with more than 356,000 out-ofhospital cardiac arrests (OHCA) occurring each year (American Heart Association, 2022). Nearly 90% of these events are fatal, and the survival rate for those treated by emergency medical services (EMS) is only about 10%. Heart attacks have a population-wide incidence rate of around 0.1%. Cardiac arrest can be fatal if not treated immediately. However, the survival rate can vary based on how quickly emergency medical services respond, the quality of CPR performed, and whether defibrillation occurs within the critical first minutes. Quick intervention has been shown to significantly improve the likelihood of survival and reduce the extent of brain injury due to lack of oxygen (American Heart Association, 2020). Once circulation is restored after cardiac arrest, another challenge arises:

ischemia/reperfusion injury. This condition occurs when blood supply to an organ is initially restricted (ischemia) and then restored (reperfusion), leading to reoxygenation that paradoxically worsens tissue damage. When blood flow returns to the organs, reperfusion injury can trigger further damage through inflammation and oxidative stress (Eltzschig & Eckle, 2011). In the case of cardiac arrest, this process is particularly critical, as the restoration of blood flow after the heart is restarted can exacerbate damage to vital organs, complicating recovery and increasing the risk of long-term dysfunction. Oxygen deprivation during cardiac arrest can lead to significant brain damage, resulting in neurological issues like memory problems, language difficulties, motor impairments, personality changes, confusion, or even coma. The severity of these complications depends on the duration of oxygen deprivation and the speed of resuscitation.

One process attempting to mitigate damages caused by ischemia/reperfusion injury is intercellular mitochondrial transfer. Mitochondria are essential for cellular energy production, and damage to these organelles during ischemia/reperfusion can lead to cell death. Recent studies suggest that mitochondria can be transferred between cells, particularly from healthy to damaged cells, potentially offering a way to restore energy production and improve cell survival. This process, known as intercellular mitochondrial transfer, involves one cell donating mitochondria to another, either through direct physical contact or extracellular vesicles. The transferred mitochondria can enhance cellular function, reduce oxidative stress, and promote survival after injury (Needs et al., 2024).

In summary, cardiac arrest is a significant and life-threatening medical emergency characterized by its high incidence and low survival rates if not addressed immediately. The restoration of blood circulation through methods such as cardiopulmonary resuscitation (CPR) and defibrillation is crucial for enhancing survival rates. Even after circulation is reestablished the body encounters additional obstacles like ischemia/reperfusion injury, which can worsen organ damage and hinder recovery. The field of intercellular mitochondrial transfer shows promise in reducing the effects of ischemia/reperfusion injury by improving cell function and survival. As research progresses, it could lead to better recovery outcomes and less invasive treatments for cardiac arrest.

Building on this promising avenue, recent attention has turned toward mitochondrial transplantation (MTx) as a potential therapeutic strategy. Mitochondria, often called the powerhouses of the cell, are essential organelles that aid in cellular energy production and overall cellular function. Recently, mitochondrial transplantation (MTx) has emerged as a potential therapy to treat various conditions, including those resulting from ischemic damage and reperfusion like, for example, cardiac arrest. Determining if mitochondria can be successfully transplanted into neural cells, improve survival and health outcomes after cardiac arrest, persist in tissues, and be stored and used after freezing are key factors in assessing the availability of this treatment.

Mitochondrial transplantation into neural cells has shown promising results in preclinical models relating to cardiac injury. The study Exogenous Mitochondrial Transplantation Improves Survival and Neurological Outcomes After Resuscitation from Cardiac Arrest highlighted the potential of mitochondrial transplantation as a therapeutic approach following cardiac arrest. This recent study showed that fresh mitochondria transplanted into rats after cardiac arrest were successfully integrated into host cells, including neurons in the brain. These transplanted mitochondria restore energy production by replenishing ATP levels that are crucial for

maintaining cellular function and preventing oxidative stress damage. This indicates that transplanted mitochondria can remain functional within the neural cells. This ability to integrate and restore mitochondrial function is key in treating conditions like cardiac arrest, where ischemic injury severely affects neural tissue, leading to cell death and impairment of neurological processes. Therefore, based on the study, mitochondrial transplantation into neural cells is not only attainable but also effective in restoring vital cellular functions.

One of the most critical aspects of mitochondrial transplantation is its potential to improve survival and health characteristics following cardiac arrest. Mitochondrial transplantation (MTx) shows significant potential for improving survival and health after cardiac arrest. In a study by (Hayashida 2023), rats that received mitochondrial transplants had a survival rate of 91%, compared to just 55% in the control group, highlighting MTx's ability to improve survival.

MTx also helped improve several key health indicators. Blood lactate levels, typically elevated due to ischemia, were notably reduced, suggesting enhanced metabolic function and better oxygen utilization. Similarly, glucose levels, which are often deregulated following cardiac arrest, were stabilized in the MTx group, supporting metabolic recovery. Neurological function improved as well, with less brain damage and reduced oxidative stress, both critical for cognitive recovery. MTx also reduced lung edema, a common complication after cardiac arrest, indicating better pulmonary function. Brain blood flow was better maintained in the transplant group, which is essential for preserving neural tissue after ischemic injury. Furthermore, MTx showed positive effects on other physiological measures, including heart ejection volume, blood pH, and CO2 levels, that propose improved cardiac and respiratory function. Rats in the transplant group also demonstrated better body weight recovery, which is typically a challenge

following ischemic events like cardiac arrest. These findings suggest that mitochondrial transplantation not only improves survival but also positively influences multiple health parameters, including metabolic function, neurological recovery, and overall physiological stability after cardiac arrest.

Despite the shown promising effects, one critical question remains: do transplanted mitochondria persist in the tissues over time? The findings from the study indicate that transplanted mitochondria remain functional in tissues for up to 24 hours after transplantation (Hayashida, 2023). This transient persistence is crucial, as it suggests that mitochondrial transplantation may be most effective as an acute intervention shortly after cardiac arrest. However, the limited persistence also implies that repeated or sustained mitochondrial support may be necessary for optimal long-term recovery. As a result, strategies to prolong the retention and function of transplanted mitochondria, such as optimizing delivery methods or combining mitochondrial transplants with other therapeutic strategies, could enhance the efficacy of this treatment.

One important factor in the success of mitochondrial transplantation is whether frozen mitochondria can be used or if they need to be fresh. Fresh mitochondria are preferred for several reasons. Freezing can damage mitochondrial membranes, proteins, and other structures, reducing their function. Mitochondria are sensitive to changes in their environment, and the freezing and thawing process can disrupt their structure, making it harder for them to work properly once transplanted. In the study by (Hayashida 2023), fresh mitochondria were successfully used, showing that the mitochondria must be in their best condition for effective transplantation. For the transplant to work, the mitochondria need to be fresh, so they can properly integrate into host

cells, especially in sensitive tissues like the brain and heart, which are vulnerable to ischemic damage.

This study underscores the potential of mitochondrial transplantation to improve survival and health after cardiac arrest by restoring mitochondrial function in neural cells and reducing damage. While fresh mitochondria are most effective, further research on delivery and retention could make this approach valuable for treating ischemic injuries and other conditions related to mitochondrial dysfunction.

References

Hayashida, Kei, et al. "Exogenous Mitochondrial Transplantation Improves Survival and Neurological Outcomes after Resuscitation from Cardiac Arrest." BMC Medicine, vol. 21, no. 1, 16 Mar. 2023, https://doi.org/10.1186/s12916-023-02759-0. Accessed 14 May 2023.

Needs, Hope I, et al. "Rescue of Mitochondrial Import Failure by Intercellular Organellar Transfer." Nature Communications, vol. 15, no. 1, 2 Feb. 2024,

https://doi.org/10.1038/s41467-024-45283-2. Accessed 6 Dec. 2024.

Newman, Mary M. "Latest Statistics | Sudden Cardiac Arrest Foundation." Www.sca-Aware.org, 2022, <u>www.sca-aware.org/about-sudden-cardiac-arrest/latest-statistics</u>.

Patel, Kevin, and John E Hipskind. "Cardiac Arrest." Nih.gov, StatPearls Publishing, 7 Apr. 2023, www.ncbi.nlm.nih.gov/books/NBK534866/.